ZBIO IMPORTANT DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Zenas BioPharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 16 Deadline in Securities Class Action First Filed by the Firm – ZBIO

Core Viewpoint - Rosen Law Firm is reminding investors of Zenas BioPharma, Inc. about the upcoming lead plaintiff deadline in a securities class action related to the company's IPO in September 2024 [1]. Group 1: Class Action Details - Investors who purchased Zenas BioPharma securities may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court by June 16, 2025, to serve as lead plaintiff [3]. - The lawsuit alleges that the Registration Statement contained false or misleading statements regarding the company's financial situation and operational funding [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4].